Biomarkers in Alzheimer’s disease: Evaluation of platelets, hemoglobin and vitamin B12

Currently, the most likely hypotheses as the cause of Alzheimer’s disease are deposition of amyloid beta peptide in the cerebral cortex and hyperphosphorylation of Tau protein. The diagnosis of Alzheimer’s disease is based on the exclusion of other diseases, behavioral assessments, and blood and imaging tests. Biotechnology has created interesting perspectives for the early detection of Alzheimer’s disease through blood analysis, with special attention to platelets, hemoglobin and vitamin B12. OBJECTIVE: To evaluate the concentrations of platelets, hemoglobin and vitamin B12 in the blood of older adults with and without dementia of Alzheimer’s disease. METHODS: A case-control study involving 120 individuals was conducted, seeking to establish a correlation between changes in platelet, hemoglobin and vitamin B12 concentrations in patients with confirmed AD and in individuals in the inclusion group without AD. The study met the established ethical requirements. RESULTS: Hemoglobin and platelet levels were statistically lower in patients with AD. The biochemical evaluation in AD patient and healthy groups for vitamin B12 showed a decrease in the levels of this compound in patients with AD. CONCLUSION: We demonstrated the feasibility of the use of blood biomarkers as predictive markers for the diagnosis of AD.